Please try another search
For the three months ended 30 June 2020, Kawasumi Laboratories, Incorporated revenues decreased 10% to Y5.12B. Net income applicable to common stockholders decreased 29% to Y124M. Revenues reflect Blood&Cardiovascular Related segment decrease of 13% to Y2.38B, Extracorporeal Circulation-Related segment decrease of 8% to Y2.75B.
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Revenue | 5124 | 5404 | 5595 | 5603 |
Gross Profit | 1816 | 1603 | 1993 | 1964 |
Operating Income | 184 | -230 | 252 | 184 |
Net Income | 125 | 241 | 779 | 201 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Assets | 44480 | 44130 | 45595 | 44965 |
Total Liabilities | 5106 | 5185 | 5721 | 5505 |
Total Equity | 39374 | 38945 | 39874 | 39460 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | 618 | 2334 | 1653 | 1717 |
Cash From Investing Activities | -178 | 234 | 1128 | -261 |
Cash From Financing Activities | -218 | -337 | -326 | -158 |
Net Change in Cash | 360 | 2121 | 2640 | 1342 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review